Printer Friendly

Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019.

NEW YORK, Jan. 8, 2015 /PRNewswire/ -- Over the last five years, the plasma fractionation market witnessed tremendous growth, primarily due to the growth in aging population, increasing number of hemophilic patients, rising use of IVIg, and high prevalence of chronic disorders across the globe. In this report, the global plasma fractionation market is divided on the basis of product, application, and end user. Based on type of products, the plasma fractionation market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. Coagulation factor concentrates are subsegmented into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates. The plasma fractionation application market is divided into neurology; hematology; immunology; critical care; and others. Likewise, the major end users analyzed in the plasma fractionation market are hospitals and clinics, clinical research laboratories, and academic institutes. The global plasma market is expected to grow at a CAGR of 8.9% during the forecast period of 2014C 2019. The market is mainly driven by the growth in aging population, increasing use of IVIg, growing number of hemophilic patients, and increasing diagnosis rate globally. However, the high cost of immunoglobulins and hemophilic drugs, stringent government regulations, and rapid increase in the use of recombinant products as an alternative to plasma-derived coagulation factor concentrates are hampering the growth of this market to a certain extent. IVIg accounts for the major share of the plasma fractionation market. The increasing use of IVIg in clinical areas such as neurology, hematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg is being evaluated for a wide range of conditions such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer's disease. Positive results in such conditions would increase the demand for IVIg globally in the near future. In 2013,, North America contribute the largest share to the global plasma fractionation market, followed by Europe, Asia-Pacific, and RoW. Developed geographies like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market, which is expected to witness the fastest growth during the forecast period, largely driven by the increasing aging population, increasing use of immunoglobulins, improved economy, rising number of hemophilic patients, growing use of albumin in China, increased accessibility to healthcare facilities, growth in the overall healthcare industry, and growing awareness of technologically advanced products in these regions. The global plasma fractionation market is mainly dominated by six players that accounted for around 70% of the global plasma fractionation market in 2013. The major players in the global plasma fractionation market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland), Laboratoire Francais du Fractionnement et des Biotechnologies (France), and Biotest (Germany). Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies (Market Penetration, Product Development/Innovation, Market Development, Market Diversification, and Competitive Assessment) for reaping greater market share. This report provides insights on the following pointers: -- Market Penetration: Comprehensive information on product portfolios offered by top players in the plasma fractionation market. The report analyzes the plasma products by products, applications, and end users across all regions. -- Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the plasma fractionation market. -- Market Development: Comprehensive information on the lucrative emerging markets by products, application, end users, and region. -- Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the plasma fractionation market. -- Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and SWOT analysis of leading players in the plasma fractionation market. Read the full report: http://www.reportlinker.com/p02590452-summary/view-report.html About Reportlinker ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/plasma-fractionation-market-by-product-albumin-immunoglobulin-factor-viii-protease-inhibitors-application-neurology-immunology-hematology-critical-care--by-end-user-hospitals-clinical-research-laboratories---global--300018136.html</a>

SOURCE Reportlinker
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 2015
Words:833
Previous Article:QIAGEN Exceeds 2014 Goal to Achieve 1,250 Cumulative QIAsymphony System Placements and Expands artus U.S. Test Menu.
Next Article:Calamos Asset Management, Inc. Announces Fourth Quarter and Year-End 2014 Investor Conference Call.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters